Similar articles

• Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease.

  Myerson M. Myerson M. Mayo Clin Proc. 2007 Jul;82(7):888; author reply 888-9. doi: 10.4065/82.7.888. Mayo Clin Proc. 2007. PMID: 17605973 No abstract available.
• When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.

  Greenland P, O'Malley PG. Greenland P, et al. Arch Intern Med. 2005 Nov 28;165(21):2454-6. doi: 10.1001/archinte.165.21.2454. Arch Intern Med. 2005. PMID: 16314539 No abstract available.
• New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.

  Tsimikas S, Tsironis LD, Tselepis AD. Tsimikas S, et al. Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2094-9. doi: 10.1161/01.ATV.0000280571.28102.d4. Epub 2007 Jul 12. Arterioscler Thromb Vasc Biol. 2007. PMID: 17626905 Review.
• C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.

  Tsimikas S, Willerson JT, Ridker PM. Tsimikas S, et al. J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C19-31. doi: 10.1016/j.jacc.2005.10.066. J Am Coll Cardiol. 2006. PMID: 16631506 Review.
• Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.

  Khakpour H, Frishman WH. Khakpour H, et al. Cardiol Rev. 2009 Sep-Oct;17(5):222-9. doi: 10.1097/CRD.0b013e3181b2434e. Cardiol Rev. 2009. PMID: 19690473 Review.